Lyon Joseph Douglas's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Mar 4, 2025
- Accession no.
- 0000950170-25-032755
- Filed
- Mar 4, 2025
- Trade date
- Feb 28-Mar 3, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $277.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lyon Joseph DouglasCIK 0001817838 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | Common Stock | FTax withholdingDisposed | −182 | $60.58F2 | −$11,025.56 | 8,577 | Direct | |
| Mar 3, 2025 | Common Stock | AGrant or awardAcquired | +216 | $59.07F5 | +$12,759.12 | 8,793 | Direct | |
| Mar 3, 2025 | Common Stock | AGrant or awardAcquired | +216 | $0.00 | $0 | 9,009 | Direct | |
| Mar 3, 2025 | Common Stock | MOption exerciseAcquired | +4,579 | $13.56 | +$62,091.24 | 13,588 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −4,579 | $60.69F8 | −$277,899.51 | 9,009 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Stock | AGrant or awardAcquired | +140,000 | $0.00 | $0 | 140,000 | Direct | |
| Mar 3, 2025 | Common Stock | MOption exerciseDisposed | −4,579 | $0.00 | $0 | 91,992 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The closing price on February 28, 2025 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
- F5
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F8
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Accounting & Technology Officer